^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    triptorelin

    i
    Other names: AY 25650, BIM 21003, BN 52014, CL 118532, Debio 8206, Debio 8206 CPP, Debio 8206 SC, WY 42422
    Company:
    Generic mfg.
    Drug class:
    GnRH agonist
    Related drugs:
    26d
    GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov)
    P1, N=181, Active, not recruiting, Genentech, Inc. | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)
    26d
    GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET (clinicaltrials.gov)
    P3, N=784, Recruiting, The University of Hong Kong | Trial completion date: Mar 2025 --> May 2026
    Trial completion date
    |
    triptorelin
    1m
    PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=692, Active, not recruiting, Janssen Pharmaceutica N.V., Belgium | Trial completion date: Aug 2029 --> Sep 2031
    Trial completion date
    |
    apalutamide • triptorelin • goserelin acetate
    1m
    A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, R-Pharm International, LLC
    New P2 trial
    |
    abiraterone acetate • triptorelin • goserelin acetate
    2ms
    SOLTI-2104: Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (clinicaltrials.gov)
    P2, N=96, Recruiting, SOLTI Breast Cancer Research Group | Active, not recruiting --> Recruiting | N=48 --> 96 | Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Dec 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    Prosigna® Breast Risk of Recurrence (ROR) Test
    |
    tamoxifen • Orserdu (elacestrant) • triptorelin
    2ms
    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (clinicaltrials.gov)
    P2, N=532, Recruiting, Mayo Clinic | Trial completion date: May 2029 --> Feb 2031 | Trial primary completion date: May 2029 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    enzalutamide • abiraterone acetate • Nubeqa (darolutamide) • apalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    2ms
    VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov)
    P2/3, N=464, Recruiting, VA Office of Research and Development | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    docetaxel • enzalutamide • abiraterone acetate • prednisone • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    2ms
    Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov)
    P3, N=2050, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Nubeqa (darolutamide) • bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
    2ms
    Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report. (PubMed, Int Cancer Conf J)
    Initially diagnosed with BRAF V600E-mutated melanoma, he received Dabrafenib and Trametinib...Despite initial treatment with Triptorelin, Docetaxel, and Abiraterone, disease progression occurred...This case illustrates the value of precision medicine and the role of liquid biopsy in guiding immunotherapy decisions for complex oncological cases. It supports the relevance of molecular profiling in selecting effective treatments beyond standard indications.
    Journal • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset)
    |
    TP53 mutation • BRAF V600E • TMB-H • BRAF V600 • ATM mutation
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • docetaxel • abiraterone acetate • triptorelin
    3ms
    Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (clinicaltrials.gov)
    P2, N=192, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • apalutamide • triptorelin • goserelin acetate • AiRuiEn (rezvilutamide)
    3ms
    OPTIMA-YOUNG: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (clinicaltrials.gov)
    P3, N=3380, Not yet recruiting, UNICANCER
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative • HER-2 expression
    |
    Prosigna® Breast Risk of Recurrence (ROR) Test
    |
    paclitaxel • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    3ms
    RADVAN: Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (clinicaltrials.gov)
    P3, N=374, Active, not recruiting, Sun Yat-sen University
    New P3 trial
    |
    triptorelin • goserelin acetate